Prediction of cross-recognition of peptide-HLA A2 by Melan-A-specific cytotoxic T lymphocytes using three-dimensional quantitative structure-activity relationships. by Fagerberg, T. et al.
Prediction of Cross-Recognition of Peptide-HLA A2 by
Melan-A-Specific Cytotoxic T Lymphocytes Using Three-
Dimensional Quantitative Structure-Activity
Relationships
Theres Fagerberg1,2., Vincent Zoete2., Sebastien Viatte1,3¤a, Petra Baumgaertner1, Pedro M. Alves1,3¤b,
Pedro Romero1, Daniel E. Speiser1, Olivier Michielin1,2,3,4*
1Department of Oncology and Ludwig Center for Cancer Research, University of Lausanne, Lausanne, Switzerland, 2 Swiss Institute of Bioinformatics, Quartier Sorge –
Baˆtiment Ge´nopode, Lausanne, Switzerland, 3National Center of Competence in Research (NCCR) Molecular Oncology, Epalinges, Switzerland, 4Multidisciplinary
Oncology Center, Lausanne University Hospital (CHUV), Lausanne, Switzerland
Abstract
The cross-recognition of peptides by cytotoxic T lymphocytes is a key element in immunology and in particular in peptide
based immunotherapy. Here we develop three-dimensional (3D) quantitative structure-activity relationships (QSARs) to
predict cross-recognition by Melan-A-specific cytotoxic T lymphocytes of peptides bound to HLA A*0201 (hereafter referred
to as HLA A2). First, we predict the structure of a set of self- and pathogen-derived peptides bound to HLA A2 using a
previously developed ab initio structure prediction approach [Fagerberg et al., J. Mol. Biol., 521–46 (2006)]. Second, shape
and electrostatic energy calculations are performed on a 3D grid to produce similarity matrices which are combined with a
genetic neural network method [So et al., J. Med. Chem., 4347–59 (1997)] to generate 3D-QSAR models. The models are
extensively validated using several different approaches. During the model generation, the leave-one-out cross-validated
correlation coefficient (q2) is used as the fitness criterion and all obtained models are evaluated based on their q2 values.
Moreover, the best model obtained for a partitioned data set is evaluated by its correlation coefficient (r= 0.92 for the
external test set). The physical relevance of all models is tested using a functional dependence analysis and the robustness
of the models obtained for the entire data set is confirmed using y-randomization. Finally, the validated models are tested
for their utility in the setting of rational peptide design: their ability to discriminate between peptides that only contain side
chain substitutions in a single secondary anchor position is evaluated. In addition, the predicted cross-recognition of the
mono-substituted peptides is confirmed experimentally in chromium-release assays. These results underline the utility of
3D-QSARs in peptide mimetic design and suggest that the properties of the unbound epitope are sufficient to capture most
of the information to determine the cross-recognition.
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Introduction
Antigenic peptides bound to Major Histocompatibility Complex
(MHC) class I molecules on the surface of antigen presenting cells
are recognized by the ab T cell receptor (TCR) on cytotoxic T
lymphocytes (CTLs) and induce the specific CD8+ T cell immune
response against virus infected cells and tumor cells.
The ab TCRs recognize the peptide-MHC class I complexes
with a certain degree of specificity that is determined by the
peptide amino acid sequence and the MHC class I allele; it has
been shown that the comprehensive response to foreign antigens
requires some level of cross-recognition, or cross-reactivity, such
that one TCR can recognize a number of different peptides in a
same MHC [1]. Interestingly, sequence homology is not neces-
sarily needed for cross-reactivity [2]. On the other hand, very
small changes in the TCR epitope can have a large impact on the
recognition [3,4]. Due to this complexity, it is difficult to predict
the existence, or extent, of cross-recognition by a TCR with a
certain specificity for different antigenic peptides. The benefits of
successful predictions would be manifold, both in the field of
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general molecular recognition principles and in the field of
immunology or immunotherapy. Indeed, they would allow for a
deeper understanding of the shaping of the T cell repertoire during
thymic maturation and its regulation in the periphery. Indirectly,
this information would provide the key elements for peptide
mimetic design, such as optimal rational design of peptidic
vaccines in anti-tumor therapy.
Experimental studies of cross-recognition, involving the analysis
of the recognition by CTL clones (of known or unknown
specificity) of synthetic combinatorial peptide libraries in positional
scanning format (PS-SCL), have recently been reported [5–8]. The
generated data together with the assumption of independent
contributions of individual side chains to antigen recognition
allowed for a quantitative biometric analysis [9]. In this analysis,
self- or pathogen-derived peptide sequences available in public
databases were scored and ranked according to their potential
reactivity and experimental recognition assays confirmed the
cross-reactivity [6]. Although this kind of approach provides an
important insight into the peptide sequence diversity in cross-
recognition, it does not give any information about the underlying
molecular recognition principles. Such information is however
crucial for efficient peptide mimetic design.
In this study, we generate three-dimensional (3D) quantitative
structure-activity relationships (QSARs) to investigate the 3D
criteria for cross-recognition by Melan-A-specific CTLs of diverse
peptide sequences bound to the human leukocyte antigen HLA A2
molecule.
The complex relationships between different properties of
molecules and their physicochemical or biological activities have
commonly been analyzed using neural networks (NN) that are
powerful in modelling non-linear relationships [10]. Moreover,
genetic algorithms (GA) can be used to select properties that are
determinant for those relationships. The usefulness of such so
called genetic neural networks (GNN) to generate QSARs from
both conventional two-dimensional (2D) descriptors [11,12], and
molecular similarity matrices (SMs) calculated from 3D molecular
fields [13,14] has been reported.
As opposed to conventional 2D descriptors, molecular SMs
represent global measures of the resemblance between a pair of
molecules based on certain properties, such as shape or
electrostatic potential, calculated on a 3D grid. An advantage in
using molecular similarity is its efficiency in reducing the raw data
dimensionality: the large raw data matrix resulting from 3D grid
calculations is compressed into a cN x N SM, where N is the
number of compounds and c is a small integer. Nevertheless, when
such a QSAR model is used to help the design of new compounds,
the use of similarity measures between molecules implies ideally
that the optimal biological result has already been achieved by one
of the training set structures, and that the design goal is to generate
other structures that are almost as good. In this particular study,
however, the goal is rather to predict the cross-recognition of
peptide-HLA by Melan-A-specific CTLs. Our training set
contains both molecules that are totally non cross-recognized on
the one hand, and highly cross-recognized on the other hand,
which allows a large range of applicability.
In our approach, we first predict the structures of a set of cross-
reactive and non-cross-reactive peptides in the HLA A2 molecule
using a previously validated in silico approach [15]. After
computing electrostatic energy and shape data on a peptide-
centric grid, we generate a molecular SM. We use the molecular
SM and a GNN method proposed by So et al. [14] with a 4-1-1
scaled conjugate gradient NN containing seven adjustable
parameters to generate 3D-QSAR models that are validated
using several different approaches. Initially, we use a partitioned
training/test set to test the 4-1-1 NN both for its ability to produce
good 3D-QSAR models, characterized by high cross-validated
correlation coefficients (q2), and its ability to accurately predict
experimental cross-reactivities for an external test set. Thereafter,
the external test set is included in the training set to produce the
final 3D-QSAR models generated for the entire data set.
Moreover, the physical validity of all obtained models is analyzed
in detail by performing a functional dependence analysis of the
individual descriptors. Finally, the robustness of the models
obtained from the entire data set is confirmed using y-random-
ization that involves identical repetitions of the calculation
procedure using randomized biological activities; no model with
better q2 and r value could be found with the randomized
activities.
In rational peptide modifications for optimization of peptidic
anti-tumor vaccines, there is often a need to substitute one or a few
side chains that improve MHC affinity without modifying the
recognition by the specific CTLs. In the parental Melan-A26–
35A27L (ELAGIGILTV) peptide, the Ala side chain at position 3
(P3), which is located in front of the hydrophobic D-pocket [16] of
HLA A2, is a so-called secondary anchor residue. Substitutions at
such secondary positions are delicate and possible conformational
changes in the peptide leading to T cell repertoire shifts must be
investigated. However, the prediction of such functional modifi-
cations based on amino acid sequence information only is
impossible. Therefore, we test if our 3D-QSAR models would
be able to discriminate between peptides with only one modified
side chain and thereby guide the design of closely related analog
peptides, despite the large divergence in peptide sequences used to
build the QSARs.
To this end, we theoretically predict the structures of all P3-
substituted analogs (referred to as ELX) of the parental Melan-
A26–35A27L peptide bound to HLA A2. After calculations on a
grid, the similarity is calculated between each ELX-HLA A2
complex and the different 3D-QSAR descriptor complexes and for
each ELX-HLA A2 complex, the cross-reactivity is predicted using
the three best 3D-QSAR models obtained previously. Importantly,
the predicted cross-recognitions are confirmed experimentally in
standard 51Cr release assays using six different Melan-A-specific
CTL clones.
Our results suggest that despite the complexity of cross-
recognition, the properties of the unbound epitope are sufficient
to capture most of the information needed, and that the use of 3D-
QSARs with high predictive ability opens the door to rational
peptide mimetic design.
Materials and Methods
1. Peptide data sets
1.1. Peptide selection for 3D-QSAR model
generation. To generate 3D-QSAR models, we use a set of
peptides identified in a recent experimental study based on
positional scanning synthetic combinatorial peptide libraries (PS-
SCLs). In the study, PS-SCLs containing C terminus amidated
decapeptides were screened with the Melan-A-specific CTL clone
LAU 203/1.5 in functional chromium-release assays [5]. The data
was used to generate a scoring matrix for the identification of
potentially cross-reactive peptide sequences of self and pathogen
origin from the GenPept protein database [6]. The cross-
recognition of the retrieved peptides by a set of 17 Melan-A-
specific CTL clones was investigated and recorded by assigning +1
for a specific lysis .10%, +2 for .20%, +3 for .40%, +4 for
.60% and 21 for lack of significant specific lysis [6]. The
recognition was measured in single dose assays with a peptide
Predicting CTL Cross-Reactivity Using QSAR
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Table 1. Selected peptides.
Peptidea Sequence Scoreb Species Protein
Human
10 LLAGIGTVPI 15 H. sapiens PG transporter
22 EAAGIGILTV 56 H. sapiens Melan-A/Mart-1
Viral
23 RQAGIAGHTY 3 HSV Capsid protein p40
25 VIAGIGILAI 39 Pseudorabies virus Glycoprotein GIII
29 NTTDIGIHVV 13 Canine calicivirus Capsid protein
30 MIAGIGISLI 16 Variola virus (XHOI-F, O, H, P, Q) genes
37 RITGICFHFG 6 Puma lentivirus 14 GAG polyprotiein
Bacterial
56 MLSGIGIFFI 11 C. trachomatis Arginine/ornithine antiporter
58 VLSSIGIFPI 3 S. Coelicolor Putative secreted protein
60 RVTGIGLLTG 9 Synechococcus sp. REPA
71 RSAFIGIDPA 15 Rhizobium sp. Y4FN probable ABC transporter permease
72 LLAGIAIGPW 12 E. coli K+/H+ antiporter
100 FLPSDFFPSV 217 Hepatitis B virus Precore/core peptide
101 KLVALGINAV 17 Hepatitis C virus Polyprotein
102 LLFNILGGWV 217 Hepatitis C virus Polyprotein
103 GLYDGMEHTV 217 H. sapiens Mage A10 with 2 mutations
104 VLYRYGSFSV 217 H. sapiens Gp-100
105 TLVEVTLGEV 217 H. sapiens Mage A2, A3, A6, n
106 LLKYRAREPV 217 H. sapiens Mage A1, A2, A3, A6
107 ALVETSYVKV 217 H. sapiens Mage A3, A12
108 VLPDVFIRCV 217 H. sapiens NA17-A
109 LLFGLALIEV 217 H. sapiens Mage C2
110 ALSRKVAELV 217 H. sapiens Mage A3, n
The 12 most cross-reactive peptide sequences from the experimental work by Rubio-Godoy et al.6 (upper part of table) were selected for structure prediction together
with a set of 11 non-cross-recognized HLA A2 binding peptide sequences (lower part of table).
aThe numbering of the cross-recognized peptides is issuing from the PS-SCL study6.
bThe cross-reactivity score was calculated from experimental cross-recognition results6, see Material and Methods.
doi:10.1371/journal.pone.0065590.t001
Figure 1. The predicted structures of the 23 selected peptides are visualized in the HLA A2 molecule (gray). The backbone (left image)
and all atoms (right image) are visualized for the cross-reactive (green) and noncross-reactive (red) peptides. The N-termini of the peptides are in the
upper part of the image. The image was generated using the Chimera program [33].
doi:10.1371/journal.pone.0065590.g001
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concentration of 1 mg/ml that in general corresponds to saturating
conditions, i.e. the measured recognition contains no contribution
from the peptide-HLA A2 affinity.
Importantly, it has been shown that Melan-A-specific CTLs
normally completely cross-recognize the Melan-A26–35 peptide
(EAAGIGILTV), i.e. peptide 22 in Table 1, and the analog
Melan-A26–35A27L peptide (ELAGIGILTV) [17]. It should
however be noted that in situations of non-saturated concentra-
tions of the peptides, the higher binding affinity of Melan-A26–
35A27L for HLA A2 results in a more efficient recognition of this
peptide [17].
Here we use the experimental cross-recognition results obtained
by Rubio-Godoy et al. [6] to score and rank their peptides from
highest to lowest cross-reactivity: for a given peptide, the score is
calculated by summing the results (+1, +2, +3, +4 or 21) from the
17 Melan-A-specific clones. This takes the overall probability of
cross-reactivity into account since a lack of cross-recognition by a
given clone is penalized by the subtraction of 21 from the score.
In its form, the cross-reactivity score is useful in the analysis of the
probability of cross-recognition by clones with a given specificity of
a peptide. The peptides used in the experimental assays [6] were
amidated at the C-terminus which might bias recognition.
However, if all or many clones recognize a peptide it can not in
all cases be only because of the amidation. Therefore, to ensure
that we use peptides that are truly cross-recognized by the clones
we select only peptides that are recognized by many (at least 7)
clones. The 12 most cross-reactive peptides (see Table 1), with
scores ranging from 56 (for the parental Melan-A26–35 peptide) to
3, are selected for 3D-QSAR generation.
Additionally, a set of 11 HLA A2 binding peptides known not to
be recognized by Melan-A-specific CTLs is selected for 3D-QSAR
generation (see Table 1). In line with the calculated score above,
each of these non-cross-recognized peptides are assigned a score of
217.
1.2. Melan-A26-35A27L P3-substituted analogs:
ELX. The Ala residue in peptide position 3 (P3) of the parental
Melan-A26–35A27L peptide (hereafter referred to ELA) is located
in front of the hydrophobic HLA A2 D-pocket [16]. Since
secondary pockets are poorly selective [16], the peptide P3
position can be substituted for all natural amino acids without
loosing HLA A2 binding, resulting in 19 ELXGIGILTV peptide
sequences (referred to as ELX).
2. In silico procedures
2.1. Prediction of peptide-HLA A2 structures. The X-ray
crystal structure of the ELA peptide in complex with HLA A2 is
available from the RCSB Protein Data Bank (http://www.rcsb.
org) with the PDB code 1JF118. The structure prediction of each
selected peptide (see Sections 2.1.1 and 2.1.2) in the HLA A2
molecule of 1JF1 is carried out as described briefly below and in
detail elsewhere [15].
A conformational sampling protocol adapted to the peptide-
MHC class I system is used: the sampling is performed using a
simple solvation model (e= 4r) and 1000 simulated annealing (SA)
heating-cooling cycles. At the end of each cycle, the conformation
of the peptide in the HLA A2 molecule is saved after energy
minimization. The complete peptide-HLA A2 complex is present
Figure 2. The backbone RMSD to the X-ray structure of the
parental peptide Melan-A26–35A27L (ELAGIGILTV) or to the
predicted structure of the parental peptide Melan-A26–35
(peptide 22; EAAGIGILTV) versus the experimental cross-
reactivity: no correlation can be observed.
doi:10.1371/journal.pone.0065590.g002
Figure 3. Correlation between the predicted and experimental
cross-reactivities for the external test set (6 complexes). The
correlation coefficient is 0.92; the slope is 0.97 and the intercept is22.1.
doi:10.1371/journal.pone.0065590.g003
Figure 4. Predicted cross-reactivity as a function of the
similarity to the four different descriptors in the model
obtained for the reduced training set (17 molecules). It can be
observed that an increased similarity to the cross-reactive peptides 22
and 25 increases the predicted cross-reactivity, while an increase in
similarity to one of the non-cross-reactive peptides 103 and 107
decreases the predicted cross-reactivity.
doi:10.1371/journal.pone.0065590.g004
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during the entire sampling. The HLA A2 molecule is kept rigid
except in two cases (peptides 23 and 72, see Table 1) where the C-
terminal side chain (TYR in 23; TRP in 72) is too large to fit into
the HLA A2 F-pocket [16]. In these cases, the side chains of Arg97
and Tyr116 are left flexible. To help keeping the N- and C-termini
of the peptide in the vicinity of the consensus conformation [16],
two NOE distance restraints (60.4 A˚ around the X-ray distances
in 1JF1) are applied to either end of the peptide. The force
constant is set to 5 kcal/(mol A˚2).
For each of the peptide-HLA A2 complexes, we select the best
conformer from the collection of 1000 sampled conformers using
an ad hoc graph theory clustering approach [15,18] to cluster the
different peptide conformers based on their pairwise heavy atom
root mean square deviation (RMSD) values. We rank the clusters
based on their conformational free energy (see Equation 1), where
the first term is the average effective energy of a cluster (see
Equation 2).
Gclu~SWTclu{TS
conf
clu zC ð1Þ
SWTclu~
1
Zclu
Xm
j~1
W (xj)e
{W (xj )=kBT ð2Þ
The effective energy, W, which is computed for each conformer,
is the sum of the intramolecular energy of the complex and the
solvation free energy of the system [19]. The salvation free energy
is computed using the Poisson-Boltzmann (PB) continuum model
for the solvent [20]. The second contribution to the conforma-
tional free energy is the conformational entropy of the cluster (see
Equation 3), where the Boltzmann probability and the partition
function are evaluated according to Equation 4 and 5.
S
conf
clu ~{kB
Xm
j~1
pjlnpj ð3Þ
pj~
e
{W (xj )=kBT
Zclu
ð4Þ
Zclu~
Xm
j~1
e
{W (xj )=kBT ð5Þ
In the equations, m is the number of members in the cluster, kB
is the Boltzmann constant and T is the absolute temperature
(T= 300 K). The term C in Equation 1 consists of the free energy
contributions from the pure solvent and the ideal contribution
from macromolecular translation and rotation; these contributions
are independent of conformation and can therefore be considered
as a constant that cancels out in the determination of relative free
energies [19]. The final structure is chosen as the centre of the
cluster with lowest conformational free energy. The centre of a
cluster is defined as the conformer having the smallest RMSD sum
to all other conformers in the cluster.
The CHARMM [21] (version c31b1) molecular modelling
program and the all-atom CHARMM22 protein parameter set
[22] are used for all calculations.
2.2. Generation of molecular similarity
matrices. Electrostatic and van der Waals interactions are the
two key components in any non-covalent ligand-receptor interac-
tion. It has been shown that QSAR predictivity obtained with the
van der Waals steric field and the shape steric field are practically
equivalent [14]. Since the shape field requires less user variables
(i.e. no truncation cut-offs etc.), we generated a double similarity
matrix (SM) based on electrostatic energy and binary shape data.
For each of the optimally superposed peptide-HLA A2 complexes,
the electrostatic energy and the shape data were computed on a
peptide-centred grid with 0.5 A˚ grid spacing. The grid size was
designed so as to extend beyond the peptide atomic coordinates of
the entire data set by at least 6 A˚. Similar conditions were used as
in So et al. [14], except that they used a grid spacing of 2 A˚ for
calculation of electrostatic energy. The same grid was used for all
complexes.
The electrostatic energy was computed with a distance-
dependent dielectric constant (e= 4r) and using a probe with a
positive unit charge. To avoid singularities for the electrostatic
energy at grid points near the atomic positions, we set the
electrostatic energy of points within the van der Waals surface of
the molecule to zero. Based on the electrostatic energy distribu-
tion, where 90.8% of the values are between +5 kcal/mol and 25
kcal/mol, we truncated electrostatic energies beyond 65 kcal/
mol.
The Hodgkin index [23],
HAB~
2
P
PAPBP
P2Az
P
P2B
ð6Þ
was used to calculate the electrostatic SM. The sum is over all grid
points and PA and PB indicate the property of interest for molecule
A and B, respectively.
The shape data was computed using a binary function that
describes whether a grid point is inside or outside the van der
Waals surface of the molecule.
Figure 5. Correlation between the predicted and experimental
cross-reactivities for the training set (23 molecules). The three
different 3D-QSAR models (black, red, green) give very similar results
(r= 0.93–0.94).
doi:10.1371/journal.pone.0065590.g005
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The Carbo´ index [24],
CAB~
P
PAPBﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃP
P2A
  P
P2B
 q ð7Þ
was used to calculate the shape SM. Note that for binary (0 or 1)
functions, the Carbo´ index reduces to the Meyer index [25],
SAB~
UABﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
TATB
p ð8Þ
that has been used for shape comparisons. In the Meyer index,
UAB is the number of grid points that are inside the common
volume of the two molecules, and TA and TB are the number of
grid points inside the individual molecular volumes.
The obtained similarity values were in the range of 0.96–1.0 for
shape and 0.74–1.0 for electrostatic energy. The lack of lower
similarity values is not a limitation since only the variation of the
values is important. As will be clear from the results, the similarity
variation is sufficient to discriminate well between different
peptides.
2.3. Genetic neural network. The genetic neural network
(GNN) method proposed by So et al. [14] was used to obtain
QSARs from a double (shape and electrostatic) molecular SM. In
this approach, a genetic algorithm (GA) is used to select molecular
descriptors and a neural network (NN) generates a non-linear
relationship between these molecular descriptors and the biolog-
ical activity score of the training set molecules (See Table 1, and
paragraph 2.1.1). For the GA we used 250 individuals and 75
evolutionary cycles to assure convergence. We used a 4-1-1 scaled
conjugate gradient NN containing 5 adjustable weights and 2
adjustable threshold parameters. The leave-one-out (LOO) cross-
validation was performed at each cycle and the cross-validated
correlation coefficient
q2~1{
PN
i~1
yi,exp{yi,pred
 2
PN
i~1
yi,exp{yi,pred
 2 ð9Þ
was used as the fitness criterion [13]. The yi,exp term is the
experimental activity and yi,pred is the predicted activity from the
LOO cross-validation. For the maximum possible correlation of
the data, q2 equals 1. A value of zero indicates that the predictions
are no better than those made randomly.
Since both the GA and the training of the NN are stochastic, we
performed 10 (training/test data set) or 50 (entire data set)
different GNN runs, each with a different seed for the random
number generator. A typical GNN calculation for the entire
peptide-HLA A2 data set (23 complexes) required about 1 central
processing unit (CPU) hour on an Athlon 64 dual core 4200+.
2.4. Data set partitioning into training and test set. The
7 adjustable parameters used in the 4-1-1 neural network allow for
a reasonable division of the entire data set (23 complexes) into a
training set of 17 complexes and an external test set of 6
complexes. Because of the small size of the entire data set, a larger
external test set could lead to over-fitting of the models obtained
using the training set. The partitioning agrees with the guidelines
issued by Golbraikh et al. [26], according to which the external test
set should include at least 5 complexes. Moreover, using a test set
of 6 complexes allows us to select 3 cross-reactive and 3 non-cross-
reactive complexes each.
The partitioning of the data set was based on ranking of the
cross-reactivity scores [26]. First, the complexes were sorted by
cross-reactivity and divided into three groups where the four most
cross-reactive complexes made up the first group, the four next
most cross-reactive complexes made up the second group etc.
Second, the three most active complexes of each group were
included in the training set and the remaining complexes in the
test set. The lack of ranking for the non-cross-reactive complexes
(all have score –17) obliged us to randomly pick 3 complexes for
the test set. The resulting external test set contained peptides 10,
56,58, 100, 104 and 108 (see Table 1).
3. Experimental procedures
3.1. Peptide-HLA A2 multimers. Peptide-HLA multimers
are complexes of refolded peptide-HLA/b2-microglobulin trimer-
ic complexes. Complexes were synthesized as earlier described
[27,28]. Briefly, purified HLA A2 heavy chain and b2-micro-
globulin were synthesized by means of a prokaryotic expression
system. The heavy chain was modified by addition of a peptide
sequence containing the BirA enzymatic biotinylation site. Heavy
chain, b2-microglobulin, and peptide were refolded. The refolded
product was biotinylated and conjugated to Streptavidin-phyco-
erythrin (-PE).
3.2. Cell lines and CTL clones. TAP-deficient T2 cells are
HLA A2 human lymphoid cells that are defective in antigen
processing, but effectively present exogenously supplied peptides
[29].
Peripheral blood mononuclear cells (PBMC) were isolated by
Ficoll-Hypaque (Beckman-Coulter, Fullerton, CA) either from a
healthy HLA A2 blood donor (BC25) or from an HLA A2
metastatic melanoma patient (LAU 203, described elsewhere [30]).
ELA-HLA A2 multimer+ CD8+ T lymphocytes were purified from
PBMC by flow cytometry cell sorting and were cloned by limiting
dilution culture in the presence of PHA, allogenic irradiated
PBMC and human recombinant IL-2, as previously described
Figure 6. Predicted cross-reactivity as a function of the
similarity to the different descriptors in the three models
obtained for the entire data set (23 molecules). The three
different models are indicated by circles, triangles and squares,
respectively. The descriptors are colored according to cross-reactivity:
cross-reactive descriptors, i.e. peptides 22 and 25, are colored green and
non-cross-reactive descriptors, i.e. peptides 103 and 105/107/110, are
colored red. It can be observed that an increased similarity to the cross-
reactive peptides increases the predicted cross-reactivity, while an
increase in similarity to one of the non-cross-reactive peptides
decreases the predicted cross-reactivity.
doi:10.1371/journal.pone.0065590.g006
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[31]. T lymphocyte clones were maintained in complete culture
medium (RPMI medium supplemented with 10% human serum,
amino acids, antibiotics) in the presence of hrIL-2 at 150 IU/ml.
Clones 25-R3 and 25-R35 are two Melan-A-specific CTL clones
derived from the healthy donor BC25. Clones 203-R1, 203-R2,
203-R3 and 203-R7 are four Melan-A-specific CTL clones
derived from the patient LAU 203. The Influenza Matrix peptide
(FluMa58–66) specific T cell clone was obtained from a healthy
donor by limiting dilution.
Written informed consent was obtained from all patients or
healthy individuals involved in this study. The study was approved
by the ethical committee of the Medical Faculty, University of
Lausanne, and the Ludwig Institute for Cancer Research.
3.3. Chromium release assay for ELX recognition. After
labelling with 51Cr during 1h at 37uC followed by extensive
washing, target cells (T2 cells) were incubated with effector cells (T
lymphocytes) at an E/T ratio of 10/1 during 4h at 37uC in V-
bottomed microtiter plates in the presence of serial dilutions of the
indicated synthetic peptide. Chromium release was measured
using LumaPlate-96 plates (PerkinElmer, Wellesley, MA) and a
TopCount-counter (PerkinElmer). The six different Melan-A-
specific CTL clones described in Section 2.3.2 were used for the
assay. Two independent experiments were performed for each
clone.
The absolute functional avidity of a CTL clone for a specific
peptide-HLA A2 complex was defined as the peptide concentra-
tion (in Molar) required to induce 50% of the maximal lysis
capacity (EC50) of the clone. To determine the absolute functional
avidity from the raw data set, a regression analysis of the linear
domain of the titration curve was performed. For comparison, the
logarithm of the relative functional avidity of a given ELX analog
to ELA was calculated: log10(EC50ELA/EC50ELX). The average
over the independent experiments was calculated.
3.4. ELX-HLA A2 competition assay. Various concentra-
tions of the competitor peptides (50ml) were incubated with 51Cr-
pulsed T2 cells (50ml; 1000 cells/well) for 15 min at room
temperature. The antigenic Influenza Matrix peptide, FluMa58–66,
was added at a concentration of 0.1 nM (50ml) together with a
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Figure 7. Scatter plot for q2 against r2 (calculated on the training set) for the three real 3D-QSAR models (red crosses) and for those
obtained with randomized cross-reactivities (black circles). The real 3D-QSAR models are well-separated from the random cases, implying
robust real models.
doi:10.1371/journal.pone.0065590.g007
Table 2. Cross-recognition results for six different Melan-A-specic CTL clones in a chromium release assay: the logarithm of the
relative functional avidity of the ELX analogs to ELA is given.
Seqa Melan-A-specic CTL clones
203-R7 25-R3 203-R2b 203-R1 203-R3 25-R35
ELA 0.00c 0.00d 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
ELS 20.59 0.14 20.41 0.13 20.07 0.00 20.01 0.10 20.99 0.01 22.44 0.50
ELT 20.19 0.32 22.17 0.11 0.09 0.00 20.05 0.15 21.88 0.08 21.59 0.62
aThe P1-P3 peptide sequence of the ELX analog.
bOnly one experiment was done with the 203-R2 clone.
cThe logarithm of the relative functional avidity of the ELX analogs compared to ELA was calculated as log10(EC50ELA/EC50ELX). A value of 21.00 means that the molar
concentration of the ELX peptide needs to be 10 times higher than ELA to achieve the same activity, i.e. 50% of maximal lysis. The average over the independent
experiments for each CTL clone is given.
dStandard deviation. By the denition of the score, the standard deviation for ELA is zero.
doi:10.1371/journal.pone.0065590.t002
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FluMa58–66-specific CTL clone (50 ml; 5000 cells/well). Chromi-
um release was measured after 4 h incubation at 37uC in a
TopCount NXTTM (Packard) plate reader. The normalized
percent specific lysis was calculated as follows: 100x(percent
specific lysis with competitor)/(percent lysis with FluMa58–66 (at
0.1 nM)).
Results and Discussion
1. Prediction of peptide-HLA A2 structures for 3D-QSAR
model generation
The conformations of the 23 selected peptides (see Table 1) in
their fixed HLA A2 environment were predicted using a
previously described ab initio approach [15]. For a brief description
of the approach, see Material and Methods. The predicted
structure of Melan-A26–35 (peptide 22 in Table 1; EAAGIGILTV),
is very similar to the X-ray crystal structure of the Melan-A26–
35A27L (ELAGIGILTV) peptide: backbone RMSD is 0.45 A˚ and
heavy atom RMSD (including Cb of the side chain in position 2) is
1.24 A˚. The predicted structures of the remaining peptides cover a
wide range of different conformations (see Figure 1) and, as shown
in Figure 2, there is no correlation between the backbone RMSD
to either ELAGIGILTV or EAAGIGILTV and the experimental
cross-reactivity (correlation coefficients r =20.05 and 20.08).
Hence, for this set of peptides with highly diverse sequences, there
is no trivial way of predicting cross-recognition by Melan-A-
specific CTLs of a peptide in HLA A2 considering only its
backbone similarities to the parental peptides (Melan-A26–35 or
Melan-A26–35A27L).
2. 3D-QSAR model generation and validation using
training/test data set
Initially, we tested the 4-1-1 neural network for both its ability to
produce good 3D-QSAR models (characterized by a high q2) and
its ability to accurately predict experimental cross-reactivities of
peptide-HLA A2 complexes for an external test set, i.e. complexes
that were not used for the model development. The entire data set
(23 complexes) was divided into a training set of 17 complexes and
an external test set of 6 complexes, see Material and Methods. No
information from the external test set was used for the model
development.
The best 3D-QSAR model is characterized by a good cross-
validated correlation coefficient (q2 = 0.75) for the training set,
indicating that the necessary, but not sufficient [32], condition for
a good 3D-QSAR model is fulfilled. To evaluate the real
predictivity of the model, the correlation coefficient (r) between
the predicted and the experimental cross-reactivities is computed
for the external test set. Indeed, the high predictive ability of the
model is confirmed with a r value of 0.92 (see Figure 3). Moreover,
a slope close to 1 (0.97) and an intercept close to 0 (22.1) is
obtained for the regression line, indicating that the model is close
to the ideal model defined by Golbraikh et al. [32]. Additionally, the
high r value for the external test set shows that the 4-1-1 neural
Figure 8. The binding affinity of ELS and ELT for HLA A2 was evaluated in competition assays. (See Material and Methods.) The average
of two independent, but very similar, results is shown: the two analog peptides competed with very similar efficiency indicating that their affinities for
HLA A2 were practically indistinguishable. Note that values are relative to specific lysis with the Influenza Matrix peptide FluMa58–66 by the FluMa58–66
specific clone and can therefore take values .100%, see Material and Methods.
doi:10.1371/journal.pone.0065590.g008
Figure 9. The heavy atom RMSD to the X-ray structure of the
parental peptide Melan-A26–35A27L (ELAGIGILTV) versus the
predicted cross-reactivity for the ELX set: a correlation can be
observed (correlation coefficient:20.84). In fact, an increased
RMSD to the parental peptide corresponds to a lower predicted cross-
reactivity.
doi:10.1371/journal.pone.0065590.g009
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network with 7 adjustable parameters is not over-fitted for the
reduced training set (17 complexes).
The physical relevance of the best 3D-QSAR model, which uses
the shape similarity to peptides 22, 25, 103 and 107 to predict the
cross-reactivity, was investigated by performing a functional
dependence analysis of the individual descriptors. Using the
model, a plot was generated for each similarity descriptor by
scanning the corresponding similarity value while keeping all other
descriptors fixed at a value equal to the average similarity observed
in the set (see Figure 4). An increased similarity to the cross-
reactive peptides 22 and 25 increases the predicted cross-reactivity,
while an increased similarity to one of the non-cross-reactive
peptides 103 and 107 decreases the predicted cross-reactivity. This
supports the validity of the model.
3. 3D-QSAR model generation and validation using the
entire data set
With the aim to produce the best possible 3D-QSAR models,
the external test set was included in the training set and 3D-QSAR
models were generated from the entire data set (23 complexes).
The three best 3D-QSAR models are from a predicitivity point
of view practically indistinguishable, such that one model could
not be chosen over the other two. They are characterized by high
cross-validated correlation coefficients (q2 = 0.78-0.79) and corre-
sponding high correlation coefficients (r= 0.93–0.94). The pre-
dicted versus the experimental cross-reactivity is plotted together
with regression lines in Figure 5. All three models have three
similarity descriptors in common: the shape similarity to peptides
22, 25 and 103. The fourth descriptor is the shape similarity to
peptide 105, 107 or 110. It is noteworthy that the best model
obtained from the partitioned training/test data set (see above)
contains the same four descriptors as one of the three models
obtained here. The best model containing at least one electrostatic
similarity descriptor is characterized by a q2 value of 0.73 and an r
of 0.87; the electrostatic similarity to peptide 22 (Melan-A26–35) is
one of the descriptors. Only the three best models (see above) will
be considered below.
As for the model obtained from the training/test data set, the
physical relevance of the models was investigated by performing a
functional dependence analysis of the individual descriptors. As
shown in Figure 6, the results are similar to those obtained for the
training/test data set. An increased similarity to the cross-reactive
peptides (22, 25) increases the predicted cross-reactivity, while an
increase in similarity to one of the non-cross-reactive peptides (103
and 105/107/110) decreases the predicted cross-reactivity. Again,
the results support the physical validity of the model.
As a final model validation, the robustness of the models was
evaluated using a so-called y-randomization: the GNN calculation
procedure was repeated with randomly shuffled cross-reactivities.
If some QSARs with high q2 values were still obtained using
randomized activities, the significance of the real QSARs (non-
randomized activities) would be suspect. A hundred different
randomizations of the cross-reactivities were performed and the 10
best models obtained for each randomization are plotted together
with the three best real 3D-QSARs in Figure 7. Noticeably, the
nature of the Y vector, which contained the same value for all the
non-cross recognized peptides, decreased the scrambling effect of
the Y-randomization procedure. This biased the Y-randomized
models toward larger q2 values compared to QSAR models
treating more conventional biological data. In addition, for each of
the 100 Y-randomizations, we have performed 50 GNN runs, and,
for the clarity of the figure, we only represented the 10 best models
for each on Figure 7 and deleted those with negative q2 values.
This procedure focused Figure 7 on the largest q2 values for the Y-
randomized models, which were indeed those leading to the most
challenging assessment of our real 3D-QSAR models. Despite this
difficult situation, it can be observed that the real 3D-QSAR
models are well-separated from the random cases, implying that
the real models cannot efficiently account for physically non-
relevant data.
To test the sensitivity of the generated models to the values
assigned for the cross-reactivities, the peptides were also scored
and ranked according to the number of clones that experimentally
recognized the peptide-HLA A2 complexes [6]. The score ranged
from 17 for the most cross-reactive peptide (peptide 22) to 0 for the
non-cross-reactive peptides. 3D-QSAR models were generated
with the 4-1-1 GNN approach: the three best models were
characterized by similar cross-validated correlation coefficient
values (q2 = 0.76–0.77) as before. Values similar to before were also
obtained for the correlation coefficient (r= 0.91–0.93) for the
training set. Importantly, the same four descriptors as before were
selected for the models: the shape similarity to peptides 22, 25, 103
and 107/110. These results show that the obtained 3D-QSAR
models were robust with respect to the type of scoring that were
used to describe the cross-reactivity. On the other hand, a binary
score, i.e. 0 for non-cross-reactive and 1 for cross-reactive, proved
to be too simplistic. Here, high q2 and r values were obtained for
models with randomized cross-reactivities.
4. Interpretation of the 3D-QSAR models
Molecular similarity indices are a very different kind of
descriptors from conventional 2D descriptors: they represent a
global measure of the resemblance between a pair of molecules
based on certain attributes, such as shape or electrostatic energy.
Therefore, although the approach described here produces
reliable 3D-QSAR models, the global character of the descriptors
is more difficult to interpret than conventional 2D descriptors.
Nevertheless, the 3D-QSAR models obtained in this study suggest
that shape similarities/differences between a given peptide-HLA A2
complex and the descriptor complexes are sufficient for a correct
prediction of the cross-reactivity of the former.
It is noteworthy that models containing electrostatic similarity
descriptors were generated with high q2 values (0.71–0.73).
Interestingly, a descriptor in common in these models is the
molecular electrostatic similarity to peptide 22, i.e. the parental
Melan-A26–35 peptide. In fact, for all 3D-QSAR models generated
from the entire data set, peptide 22 was selected as either a shape
or an electrostatic similarity descriptor. The omnipresence of the
Melan-A26–35 peptide as a similarity descriptor to predict cross-
recognition by Melan-A-specific CTLs is expected since QSAR
models, in order to be highly predictive, may need to select a
descriptor corresponding to a highly active compound.
The lack of electrostatic descriptors in the three best 3D-QSAR
models obtained in this study is likely due to the overall non-polar
character of the parental Melan-A26–35 (EAAGIGILTV) and the
overall non-polar character observed in most cross-reactive
peptide amino acid sequences (see Table 1). It is, however, less
expected to find that the descriptors based on the similarity to non-
cross-reactive peptides are related to shape, even though these
sequences in general contain a significant number of polar or
charged side chains. Moreover, based on previously published X-
ray crystallographic structures, hydrogen bonds are known to be
important in the interaction between TCR and peptide-MHC,
and an addition of 2D descriptors mapping such putative contacts
could be useful to generate QSAR models with high predictive
power.
No simple linear relationship could be observed between the
shape similarity to individual descriptors and the experimental
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activity (data not shown). Hence, the high predictivity of the 3D-
QSAR models suggests that the generated non-linear relationship
between several shape similarity descriptors and cross-reactivities is
crucial for the successful outcome.
Together, these results suggests that the 3D-QSAR models are
very efficient, and that a non-linear relationship is indeed
necessary for successful prediction of the probability of cross-
recognition by Melan-A-specific CTLs of peptides with diverse
sequences. Finally, although the absence of TCR influence in the
structure predictions may be a source of error in the prediction of
cross-reactivity based on those structures, the results suggest that
properties of the unbound epitope are sufficient to capture most of
the information to determine the cross-reactivity.
5. Application of the 3D-QSAR models to rational peptide
modifications: an additional external test set
Above we show that the 3D-QSAR models are successful in
discriminating between cross-reactive and non-cross-reactive
peptides with diverse sequences. Here, we test if these 3D-QSAR
models are able to discriminate between peptides with only one
modified side chain and thereby guide the design of closely related
analog peptides, despite the large divergence in peptide sequences
used to build the QSARs.
To this end, we theoretically predict the structures of all P3-
substituted analogs of the parental Melan-A26–35A27L peptide
bound to HLA A2, referred to as ELX-HLA A2, see Material and
Methods. After shape data calculation on the same grid as before,
the similarity is calculated between each ELX-HLA A2 complex
and the different 3D-QSAR descriptor complexes, i.e. peptide 22,
25, 103 and 105/107/110. For each ELX peptide, its cross-
reactivity is predicted using each of the three 3D-QSAR models.
According to a consensus scoring approach [11], the final
predicted cross-reactivity for each analog peptide is calculated as
the average of the results from the three models. Although
spanning a wide range, i.e. from 27 (for ELS) to 212 (for ELW),
the values are within the range of the experimental cross-
reactivities, see Table 1. Interestingly, the score for ELS indicates
that it should be very highly cross-recognized by Melan-A-specific
CTLs. On the contrary, ELY (score =28), ELK (-10) and ELW (-
12) should not be cross-recognized. Most other ELX peptides, like
the second (ELC: 20) and third (ELG: 18) best scored peptides,
should be expected to be well recognized although to a lesser
degree than the ELS peptide. Interestingly, ELT (0) belongs to
these peptides. Hence, although this analog peptide contains
threonine that has similar physico-chemical properties as serine,
except for the larger volume due to the additional methyl group, it
is predicted to be less cross-recognized than ELS (27).
To test if these theoretical results can be confirmed experimen-
tally, we evaluated the cross-recognition by six different Melan-A-
specific CTL clones in standard 51Cr release assays, see Material
and Methods. The experimental relative cross-recognition of ELS
and ELT peptides versus the parental peptide by the six different
Melan-A-specific CTL clones is given in Table 2. It can be
observed that the ELS analog is more frequently cross-recognized
than the ELT analog: whereas 5 of 6 Melan-A-specific CTLs
recognize the ELS analog within 1.5 log of the parental peptide,
only 3 of 6 CTLs recognize the ELT analog. Moreover, the
average cross-recognition relative to ELA over all six CTL clones
is 20.75 for ELS and 20.97 for ELT, again showing the higher
cross-reactivity of ELS compared to ELT.
In these assays, saturating conditions are not satisfied and
potential differences in ELX-HLA A2 binding affinity might
contribute to the cross-recognition results. In order to exclude that
the cross-recognition results obtained for the ELS and ELT
analogs were due to differences in affinity for HLA A2, we
performed competition assays using either peptide as competitor,
see Material and Methods. The competition results from two
independent experiments are very similar and the average of
normalized specific lysis (%) from the two experiments is plotted in
Figure 8. The two analog peptides compete with very similar
efficiency indicating that their affinities for HLA A2 are practically
indistinguishable and that the observed differences in cross-
recognition (see above) are mainly due to the interaction of the
TCRs with peptide-HLA A2.
In contrast to the lack of correlation between RMSD and cross-
reactivity observed for the diverse data set used for 3D-QSAR
model generation (Figure 2), here we observe a correlation
between RMSD to the parental ELA peptide and the predicted
cross-reactivity of ELX, see Figure 9. In fact, heavy atom RMSD
values between the predicted structures of the ELX peptides and
the X-ray structure of ELA (excluding side chain atoms beyond
Ca at the substitution site) is linearly related to the predicted cross-
reactivity of ELX with a correlation coefficient of 20.84. Similar
results were obtained using backbone RMSD values (correlation
coefficient: 20.89).
Taken together, these results show that for mono-substituted
peptides the RMSD to the parental peptide is sufficient for
determining whether a peptide will be cross-reactive or not.
However, the results also show that the 3D-QSAR models
obtained from the data set of diverse peptide sequences (see
Table 1) are equally successful in discriminating between peptides
with single amino acid substitutions.
Conclusion
In this study, we have investigated the use of 3D-QSARs in the
prediction of the probability of cross-recognition by Melan-A-
specific CTLs of peptides with different sequences. We show that
the use of 3D molecular descriptors (in the form of a similarity
matrix) and a 4-1-1 genetic neural network allow for the
generation of robust 3D-QSAR models that are characterized
by a high predictive ability as evaluated on both a partitioned
training/test set and the entire data set of highly diverse peptide
sequences. Moreover, the 3D-QSARs could not be replaced by
trivial correlations between structure and cross-reactivity. Appli-
cation of the 3D-QSARs to an additional external test set of mono-
substituted peptides shows that the models are also capable of
distinguishing between different degrees of cross-reactivity for
these peptides. Importantly, experiments confirm the theoretical
results.
Taken together, our results suggest that 3D-QSARs can be
highly successful in predicting the probability of cross-recognition
by specific CTLs of different peptides. This allows for efficient
rational peptide mimetic design.
Supporting Information
Appendix S1 HLA-A2-1jf1.pdb. 3D structure of the HLA-A2
molecule used for the docking. It corresponds to the 1JF1 entry of
the PDB.
(PDB)
Appendix S2 peptides dock4.pdb. 3D structures for the
calculated binding modes of the 23 peptides shown in Figure 1. In
PDB format, following the dock4 specifications to make the
visualization easier in UCSF Chimera, using the ViewDock
plugin. In the right-most column, – 3SG corresponds to the
peptides shown in Figure 1. – 1SG corresponds to 2 residues of
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HLA-A2 (Arg97 and Tyr116) that were considered flexible during
the docking of peptides 23 and 72.
(PDB)
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